The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
Abstract Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti-angiogenic therapy was beneficial to the EGFR L858R subpopulation was inconclusive. A retrospective study was conducte...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-18889-z |
| _version_ | 1817999052735774720 |
|---|---|
| author | Liangkun You Xinnan Zheng Danchen Deng Hongming Pan Weidong Han |
| author_facet | Liangkun You Xinnan Zheng Danchen Deng Hongming Pan Weidong Han |
| author_sort | Liangkun You |
| collection | DOAJ |
| description | Abstract Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti-angiogenic therapy was beneficial to the EGFR L858R subpopulation was inconclusive. A retrospective study was conducted to investigate the survival benefit and the target characteristics of the anti-angiogenic agent in the EGFR L858R patients in our center, comparing those treated with or without anti-angiogenic therapy (cohort A and cohort B). At the median follow-up time of 31.0 months vs 32.7 months (cohort A vs. B) respectively, Cohort A (n = 58) had a significantly prolonged median OS compared to Cohort B (n = 101) (60.0 months vs.37.0 months, HR 0.51, p = 0.016). Anti-angiogenic therapy significantly prolonged the OS in patients with liver metastases (NA vs.26.0 months, HR 0.17, p = 0.023) comparing to patients without liver metastases (60.0 months vs.37.0 months, HR 0.63, p = 0.129). For brain metastatic patients, anti-angiogenic treatment tended to improve median OS with (65.0 months vs.35.0 months, HR 0.29, p = 0.068) or without brain radiotherapy (73.0 months vs.29.0 months, HR 0.24, p = 0.171). The grade 3 or more adverse events were manageable and consistent with previous studies. Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never received an anti-angiogenic agent. Patients with liver metastases might benefit more from anti-angiogenic therapy than those without. |
| first_indexed | 2024-04-14T03:02:48Z |
| format | Article |
| id | doaj.art-824d99bd61344ea293fd03a6877473c6 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-14T03:02:48Z |
| publishDate | 2022-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-824d99bd61344ea293fd03a6877473c62022-12-22T02:15:51ZengNature PortfolioScientific Reports2045-23222022-08-0112111010.1038/s41598-022-18889-zThe benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective studyLiangkun You0Xinnan Zheng1Danchen Deng2Hongming Pan3Weidong Han4Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineAbstract Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti-angiogenic therapy was beneficial to the EGFR L858R subpopulation was inconclusive. A retrospective study was conducted to investigate the survival benefit and the target characteristics of the anti-angiogenic agent in the EGFR L858R patients in our center, comparing those treated with or without anti-angiogenic therapy (cohort A and cohort B). At the median follow-up time of 31.0 months vs 32.7 months (cohort A vs. B) respectively, Cohort A (n = 58) had a significantly prolonged median OS compared to Cohort B (n = 101) (60.0 months vs.37.0 months, HR 0.51, p = 0.016). Anti-angiogenic therapy significantly prolonged the OS in patients with liver metastases (NA vs.26.0 months, HR 0.17, p = 0.023) comparing to patients without liver metastases (60.0 months vs.37.0 months, HR 0.63, p = 0.129). For brain metastatic patients, anti-angiogenic treatment tended to improve median OS with (65.0 months vs.35.0 months, HR 0.29, p = 0.068) or without brain radiotherapy (73.0 months vs.29.0 months, HR 0.24, p = 0.171). The grade 3 or more adverse events were manageable and consistent with previous studies. Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never received an anti-angiogenic agent. Patients with liver metastases might benefit more from anti-angiogenic therapy than those without.https://doi.org/10.1038/s41598-022-18889-z |
| spellingShingle | Liangkun You Xinnan Zheng Danchen Deng Hongming Pan Weidong Han The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study Scientific Reports |
| title | The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study |
| title_full | The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study |
| title_fullStr | The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study |
| title_full_unstemmed | The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study |
| title_short | The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study |
| title_sort | benefit of anti angiogenic therapy in egfr exon 21 l858r mutant non small cell lung cancer patients a retrospective study |
| url | https://doi.org/10.1038/s41598-022-18889-z |
| work_keys_str_mv | AT liangkunyou thebenefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT xinnanzheng thebenefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT danchendeng thebenefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT hongmingpan thebenefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT weidonghan thebenefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT liangkunyou benefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT xinnanzheng benefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT danchendeng benefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT hongmingpan benefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy AT weidonghan benefitofantiangiogenictherapyinegfrexon21l858rmutantnonsmallcelllungcancerpatientsaretrospectivestudy |